{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:24:10Z","timestamp":1774351450428,"version":"3.50.1"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The Health Management and Economics Research Center, Iran University of Medical Sciences","award":["23298-113-1-1401"],"award-info":[{"award-number":["23298-113-1-1401"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our aim was to systematically review the cost-effectiveness of proton pump inhibitor (PPI) therapies and surgical interventions for gastro-oesophageal reflux disease (GORD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The study design was a systematic review of economic evaluations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>We searched PubMed, Embase, Scopus, and Web of Science for publications from January 1990 to March 2023. Only articles published in English were eligible for inclusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria<\/jats:title>\n                  <jats:p>Studies were included if they were full economic evaluations comparing PPIs with surgical or alternative therapies for GORD. Excluded were narrative reviews, non-peer-reviewed articles, and studies not reporting cost-effectiveness outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data extraction and synthesis<\/jats:title>\n                  <jats:p>Two reviewers independently extracted data on study design, comparators, time horizon, and cost-effectiveness outcomes. The quality of studies was assessed using the Joanna Briggs Institute (JBI) checklist for economic evaluations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 25 studies met the inclusion criteria. Laparoscopic Nissen fundoplication (LNF) was found to be cost-effective in long-term horizons, while PPIs were preferred for short- to medium-term outcomes. Differences in healthcare settings and methodological approaches influenced the study findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Strategic purchasing decisions for GORD treatment should consider the time horizon, healthcare setting, and cost structures. LNF may provide better long-term value, but PPIs remain effective for managing symptoms in the short term.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study registration<\/jats:title>\n                  <jats:p>PROSPERO, CRD42023474181.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2024-001465","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T23:50:22Z","timestamp":1734738622000},"page":"e001465","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Economic evaluation of proton pump inhibitors in patients with gastro-oesophageal reflux disease: a systematic review"],"prefix":"10.1136","volume":"11","author":[{"given":"Seidamir Pasha","family":"Tabaeian","sequence":"first","affiliation":[{"name":"1Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7193-1812","authenticated-orcid":false,"given":"Sajad","family":"Moeini","sequence":"additional","affiliation":[{"name":"Department of Health Services Management, School of Health Management & Information Sciences, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[{"name":"1Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayeh","family":"Afshari","sequence":"additional","affiliation":[{"name":"1Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aghdas","family":"Souresrafil","sequence":"additional","affiliation":[{"name":"Department of Health Services and Health Promotion, School of Health, Occupational Environment Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Barzegar","sequence":"additional","affiliation":[{"name":"Department of English Language, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025073013213380000_11.1.e001465.1","unstructured":"MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US) . Proton pump inhibitors. [reviewed 2023 May 3;] Available: https:\/\/medlineplus.gov\/ency\/patientinstructions\/000381.htm"},{"key":"2025073013213380000_11.1.e001465.2","unstructured":"El-serag hb, sweet s, winchester cc, dent j. update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. gut [internet]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/23853213\/"},{"key":"2025073013213380000_11.1.e001465.3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5056\/jnm19188","article-title":"Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea","volume":"26","author":"Park","year":"2020","journal-title":"J Neurogastroenterol Motil"},{"key":"2025073013213380000_11.1.e001465.4","doi-asserted-by":"crossref","unstructured":"Richter JE, Rubenstein JH . Presentation and epidemiology of gastroesophageal reflux disease. gastroenterology. 2018 jan;154(2):267-276. doi:10.1053\/j.gastro.2017.07.045","DOI":"10.1053\/j.gastro.2017.07.045"},{"key":"2025073013213380000_11.1.e001465.5","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719893378"},{"key":"2025073013213380000_11.1.e001465.6","unstructured":"National Health Service (NHS Digital) . Prescription cost analysis -england (2020\/2021). 2020. Available: https:\/\/www.statista.com\/statistics\/378445\/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england\/"},{"key":"2025073013213380000_11.1.e001465.7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1747493019879658","article-title":"Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors","volume":"16","author":"Luengo-Fernandez","year":"2021","journal-title":"Int J Stroke"},{"key":"2025073013213380000_11.1.e001465.8","doi-asserted-by":"crossref","unstructured":"Grant A , Boachie C , Cotton S , et al . n.d. Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial). Health Technol Assess 17:1. doi:10.3310\/hta17220","DOI":"10.3310\/hta17220"},{"key":"2025073013213380000_11.1.e001465.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"2025073013213380000_11.1.e001465.10","doi-asserted-by":"publisher","DOI":"10.1332\/174426410X482999"},{"key":"2025073013213380000_11.1.e001465.11","first-page":"231","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"V Health"},{"key":"2025073013213380000_11.1.e001465.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2576","article-title":"Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study","volume":"339","author":"Epstein","year":"2009","journal-title":"BMJ"},{"key":"2025073013213380000_11.1.e001465.13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/13696998.2023.2201063","article-title":"Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease","volume":"26","author":"Harper","year":"2023","journal-title":"J Med Econ"},{"key":"2025073013213380000_11.1.e001465.14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/bjs.9190","article-title":"Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial","volume":"100","author":"Faria","year":"2013","journal-title":"Br J Surg"},{"key":"2025073013213380000_11.1.e001465.15","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725100-00003"},{"key":"2025073013213380000_11.1.e001465.16","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4933"},{"key":"2025073013213380000_11.1.e001465.17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00019053-200523100-00006","article-title":"Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease","volume":"23","author":"Hughes","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"2025073013213380000_11.1.e001465.18","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1185\/030079905X65330","article-title":"Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK","volume":"21","author":"Rem\u00e1k","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2025073013213380000_11.1.e001465.19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00019053-200220040-00005","article-title":"Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies","volume":"20","author":"Wahlqvist","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"2025073013213380000_11.1.e001465.20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.surg.2014.05.027","article-title":"Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease","volume":"157","author":"Funk","year":"2015","journal-title":"Surgery"},{"key":"2025073013213380000_11.1.e001465.21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1572-0241.2000.01759.x","article-title":"A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease","volume":"95","author":"Gerson","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2025073013213380000_11.1.e001465.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30891.x"},{"key":"2025073013213380000_11.1.e001465.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70118-5"},{"key":"2025073013213380000_11.1.e001465.24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00019053-199400053-00009","article-title":"Economic Evaluation of Treatment of Gastro-Oesophageal Reflux Disease in the United States","volume":"5","author":"Bloom","year":"1994","journal-title":"Pharmacoeconomics"},{"key":"2025073013213380000_11.1.e001465.25","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2169\/internalmedicine.2535-18","article-title":"Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan","volume":"58","author":"Habu","year":"2019","journal-title":"Intern Med"},{"key":"2025073013213380000_11.1.e001465.26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jgf2.429","article-title":"Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan","volume":"22","author":"Habu","year":"2021","journal-title":"J Gen Fam Med"},{"key":"2025073013213380000_11.1.e001465.27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.21037\/atm-22-1722","article-title":"Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China","volume":"10","author":"Wang","year":"2022","journal-title":"Ann Transl Med"},{"key":"2025073013213380000_11.1.e001465.28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1365-2036.2003.01526.x","article-title":"Low\u2010dose or standard\u2010dose proton pump inhibitors for maintenance therapy of gastro\u2010oesophageal reflux disease: a cost\u2010effectiveness analysis","volume":"17","author":"You","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013213380000_11.1.e001465.29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1155\/2008\/765458","article-title":"The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis","volume":"22","author":"Comay","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"2025073013213380000_11.1.e001465.30","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200208000-00007"},{"key":"2025073013213380000_11.1.e001465.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365529609031619","article-title":"Cost Effectiveness of Medical versus Surgical Treatment in Patients with Severe or Refractory Gastroesophageal Reflux Disease in The Netherlands","volume":"31","author":"Van Den Boom","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"2025073013213380000_11.1.e001465.32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00044011-200525050-00005","article-title":"Proton pump inhibitors in acute treatment of reflux oesophagitis\u202f: a cost-effectiveness analysis","volume":"25","author":"Lucioni","year":"2005","journal-title":"Clin Drug Investig"},{"key":"2025073013213380000_11.1.e001465.33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/cer.15.63","article-title":"Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?","volume":"5","author":"Petryszyn","year":"2016","journal-title":"J Comp Eff Res"},{"key":"2025073013213380000_11.1.e001465.34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1368-5031.2005.00563.x","article-title":"Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting","volume":"59","author":"Hansen","year":"2005","journal-title":"Int J Clin Pract"},{"key":"2025073013213380000_11.1.e001465.35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00019053-199916050-00006","article-title":"Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease","volume":"16","author":"St\u00e5lhammar","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"2025073013213380000_11.1.e001465.36","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0164-8"},{"key":"2025073013213380000_11.1.e001465.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-024-11781-8","article-title":"Diagnosis and treatment of patients with gastroesophageal reflux disease - a systematic review of cost-effectiveness and economic burden","volume":"24","author":"Maresova","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2025073013213380000_11.1.e001465.38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00535-019-01609-2","article-title":"Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD","volume":"54","author":"Yokoya","year":"2019","journal-title":"J Gastroenterol"},{"key":"2025073013213380000_11.1.e001465.39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s41669-024-00521-7","article-title":"The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System","volume":"8","author":"Harper","year":"2024","journal-title":"PharmacoEconomics Open"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2024-001465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:21:47Z","timestamp":1753906907000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2024-001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,20]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjgast-2024-001465"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2024-001465","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}